Orexo AB (OSTO:ORX) EBIT: kr-221.1 Mil (TTM As of Mar. 2026)


OSTO:ORX Orexo AB OSTO:ORX
49 GF Score
Price kr22.55
GF Value kr6.45
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB EBIT?

Orexo AB OSTO:ORX +0.22% 49 EBIT is kr-221.1 Mil as of Mar. 2026. GuruFocus rates OSTO:ORX with a GF Score™ of 49/100 and a GF Value™ of kr6.45 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Orexo AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-74.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-221.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Orexo AB's annualized ROC % for the quarter that ended in Mar. 2026 was -89.81%. Orexo AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -561.57%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Orexo AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -53.55%.

Orexo AB  (OSTO:ORX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Orexo AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-299.6 * ( 1 - 0% )/( (355.8 + 311.4)/ 2 )
=-299.6/333.6
=-89.81 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1302.8 - 96.9 - ( 912.4 - max(0, 314.7 - 1164.8+912.4))
=355.8

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=610.4 - 57.9 - ( 386.2 - max(0, 235.2 - 476.3+386.2))
=311.4

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Orexo AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-299.6/( ( (56.4 + max(-98.2, 0)) + (50.3 + max(-214.5, 0)) )/ 2 )
=-299.6/( ( 56.4 + 50.3 )/ 2 )
=-299.6/53.35
=-561.57 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(184.7 + 0 + 24.1) - (96.9 + 0 + 210.1)
=-98.2

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(16.6 + 0 + -0.099999999999966) - (57.9 + 0 + 173.1)
=-214.5

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Orexo AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-221.1/412.915
=-53.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB EBIT Related Terms

Orexo AB EBIT Historical Data

* Premium members only.

The historical data trend for Orexo AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB EBIT Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -194.30 -142.60 -99.10 -417.50 -352.80

Orexo AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.30 -21.50 -21.40 -103.30 -74.90

OSTO:ORX vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orexo AB EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Orexo AB's EV-to-EBIT falls into.


OSTO:ORX
49GF Score
Orexo AB OSTO:ORX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-221.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-221.1 Mil mean?
Orexo AB (OSTO:ORX) has a EBIT of kr-221.1 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Orexo AB.
Is Orexo AB's EBIT too high?
Orexo AB's current EBIT is kr-221.1 Mil. Overall, Orexo AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's EBIT compare to ZTS?
Orexo AB's EBIT of kr-221.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Orexo AB. Orexo AB's current EBIT is kr-221.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (OSTO:ORX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.45, compared to a current price of kr22.55 — trading 249.6% above its estimated fair value. The current EBIT is kr-221.1 Mil. Orexo AB's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Orexo AB (OSTO:ORX), the current EBIT is kr-221.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (OSTO:ORX) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of kr22.55 is trading 249.6% above its estimated GF Value™ of kr6.45. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for OSTO:ORX:

  • EBIT: kr-221.1 Mil
  • GF Value™: kr6.45 vs. price of kr22.55 (249.6% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the OSTO:ORX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
49GF Score

Get the complete analysis for OSTO:ORX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr22.55
Price
kr6.45
GF Value